Table 1.

Clinical and demographic characteristics by treatment arm (safety population)

CharacteristicFerumoxytolIron Sucrose
Patients (N)8082
Age (yr), mean±SD62±1563±15
Sex, n (%)
 Women41 (51)39 (47)
Race, n (%)
 White52 (65)62 (76)
 Black/African American21 (26)14 (17)
 Asian4 (5)1 (1)
 Native Hawaiian or other Pacific Islander2 (3)1 (1)
 Other1 (1)3 (4)
Dialysis status, n (%)
 Hemodialysis34 (43)36 (44)
Baseline hemoglobin level (g/dl), n (%)
 >7 to ≤910 (13)11 (13)
 >9 to <1170 (87)71 (87)
CKD stage, n (%)
 2 (GFR=60 to <90 ml/min per 1.73 m2)5 (6)0
 3 (GFR=30 to <60 ml/min per 1.73 m2)15 (19)19 (23)
 4 (GFR=15 to <30 ml/min per 1.73 m2)22 (27)20 (24)
 5 (GFR<15 ml/min per 1.73 m2)38 (48)42 (51)
 Unknown01 (1)
Erythropoiesis-stimulating agent therapy, n (%)
 Yes44 (55)40 (49)